[{"id":"da7c1c4e-12fb-4361-97e1-5845011e3482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243190","created_at":"2021-01-18T05:00:24.541Z","updated_at":"2025-02-25T13:16:23.958Z","phase":"Phase 2","brief_title":"Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT01243190","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH • CD38","pipe":" | ","alterations":" CD38 positive","tags":["IGH • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 03/28/2023","study_completion_date":" 03/28/2023","last_update_posted":"2024-09-19"},{"id":"8c189e73-7839-42ec-89f2-d58afc05f72f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04177823","created_at":"2021-01-18T20:22:29.877Z","updated_at":"2024-07-02T16:35:08.515Z","phase":"Phase 1","brief_title":"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","source_id_and_acronym":"NCT04177823","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8","pipe":" | ","alterations":" CD38 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-04-19"},{"id":"f1cfe322-7c0f-4270-b499-e5b443eefa43","acronym":"CARLOTTA01","url":"https://clinicaltrials.gov/study/NCT05836896","created_at":"2023-05-01T14:03:57.086Z","updated_at":"2024-07-02T16:35:18.546Z","phase":"Phase 1","brief_title":"A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","source_id_and_acronym":"NCT05836896 - CARLOTTA01","lead_sponsor":"Technische Universität Dresden","biomarkers":" CD31 • SLAMF7","pipe":" | ","alterations":" CD38 positive","tags":["CD31 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDC-CAR-BCMA001"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-20"},{"id":"7f239492-f11c-4e34-b238-37cd373c3cec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03766763","created_at":"2021-01-18T18:38:18.690Z","updated_at":"2024-07-02T16:36:06.608Z","phase":"Phase 2","brief_title":"Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A","source_id_and_acronym":"NCT03766763","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" CD20 • CD200","pipe":" | ","alterations":" CD20 positive • CD38 positive","tags":["CD20 • CD200"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 01/22/2022","primary_completion_date":" 01/22/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2022-07-27"},{"id":"5fad71d4-a395-4a9d-9bc6-39b3d673e45a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01276236","created_at":"2021-01-29T07:01:30.935Z","updated_at":"2024-07-02T16:36:33.752Z","phase":"Phase 2","brief_title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","source_id_and_acronym":"NCT01276236","lead_sponsor":"University of California, San Francisco","biomarkers":" CD8 • CD38 • CD4 • CD69","pipe":" | ","alterations":" CD38 positive • CD8 negative","tags":["CD8 • CD38 • CD4 • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive • CD8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/09/2011","start_date":" 03/09/2011","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2021-03-05"}]